November 2022 - Page 2 of 3 - PsychedelicNewsWire (PNW)

MondayNov 14, 2022 11:27 am

National Park Service Warns Visitors Off Licking Psychedelic Toads

The Sonoran desert toad is among the largest toads in continental North America. Measuring an average of seven inches, this species of toad is known to secrete an alkaloid on its skin that causes psychedelic-like effects when ingested. Over the past few years, more and more people have begun taking part in a trend that involves licking the back of toads to achieve a psychedelic high. However, the alkaloid that produces these effects in humans is actually a toxin secreted by the toad to ward off predators. On top of that, not all toads secrete this toxin; licking secretions from…

FridayNov 11, 2022 1:44 pm

Research Discovers That LSD Triggers Afterglow, Hangover for Various Mental Functions

For decades, LSD has been one of the most popular recreational psychedelics despite being outlawed by the federal and state governments. In recent years, however, more and more people have begun using psychedelics such as LSD medicinally as an increasing number of studies have shown that hallucinogenic drugs can have mental health benefits. Initial studies have revealed that LSD may be able to alleviate the symptoms of social anxiety disorders and autism spectrum disorders. In addition, a recent study, whose findings were reported in the “European Neuropsychopharmacology” journal, has now found that LSD may also be able to induce both…

ThursdayNov 10, 2022 10:42 am

Frustrated with VA, US Veterans Go Overseas for Psychedelic Treatment

In recent years, emerging studies involving psychedelics have found that hallucinogenic drugs can be effective at treating a variety of mental health conditions. These clinical trials and studies have revealed that when paired with psychotherapy, psychedelics can result in positive and profound long-term outcomes for patients suffering from conditions such as depression and post-traumatic stress disorder (PTSD). Coincidentally, these mental health issues have plagued military veterans for decades and resulted in the deaths of countless vets. Some studies show that around 14% to 16% of Iraq and Afghanistan war veterans suffer from depression or PTSD. Although psychedelics could be used…

WednesdayNov 09, 2022 11:44 am

Ethnicity, Race Could Impact Psychedelic Therapy Outcomes

In recent years, an upsurge in psychedelic research among the scientific community has led to the discovery of psychedelic-assisted therapies capable of alleviating a variety of mental health conditions. Studies have found that psychedelics can be effective at treating mental health conditions such as post-traumatic stress disorder (PTSD), depression, and eating disorders when paired with psychotherapy. Although researchers aren’t certain how psychedelics such as psilocybin and LSD have these effects, we know that the psychedelic experience plays a major role in therapy. But with psychedelic research still in its infancy, there is little concrete data available regarding how hallucinogenic drugs…

TuesdayNov 08, 2022 1:41 pm

A New Book Explores Hollywood Legend Cary Grant’s LSD Therapy

Edward J. Delaney, an American author who’s written fictional books such as “Follow the Sun” and “Warp and Weft,” recently published a new novel based on the life of Cary Grant. The novel in question, “The Acrobat,” focuses on Grant’s use of LSD as part of his psychotherapy at a time when the psychedelic was still legal in America. Cary Grant was an English-American actor, born Archibald Alexander Leach in January 1904, England. He was the second child of Elias and Elsie Maria Leach, who worked as a tailor’s presser and seamstress, respectively. Archibald’s mother taught him dance and song…

MondayNov 07, 2022 10:52 am

New Psychedelic Journal to Focus on Publishing Psychedelic Research

The psychedelic medicine field is growing rapidly, as centers devoted to the study of psychedelic drugs continue to expand across Europe and North America. A new peer-reviewed journal, “Psychedelic Medicine,” will focus on publishing articles on the status of investigational psychedelic drugs in clinical trials and advances made in psychedelic research. The journal’s editorial board members agreed that the board would mainly center on serotonergic agonists and proposed that the term “psychedelic” be used in a broader sense scientifically. At the moment, the term “psychedelic” is normally used to describe psychoactive drugs that possess a primary mechanism of action which…

FridayNov 04, 2022 12:58 pm

NIH Funds Research to Investigate Psilocybin’s Effectiveness in Helping Smokers Quit

The National Institutes of Health has awarded a grant to researchers at Johns Hopkins University to find out whether psychedelics can help smokers quit smoking. This is the first time in decades that a federal grant has been awarded to carry out research on a psychedelic as a potential treatment. We have seen interest in psychedelics grow significantly these last few years, especially as more studies find that these drugs may be useful in the treatment of a range of mental health disorders, including post-traumatic stress disorder, depression and addiction. For instance, research published a few months ago found that…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

ThursdayNov 03, 2022 2:01 pm

DiPT: The Psychedelic That Causes Auditory Hallucinations

DiPT (N,N-diisopropyltryptamine) is a psychedelic drug of the tryptamine family that induces auditory hallucinations. This means that unlike other hallucinogens which cause visual hallucinations by affecting an individual’s visual sense, DiPT causes hallucinations where an individual can hear sounds. DiPT was first created and experimented with by Alexander Shulgin in 1980. It is chemically related to DMT, which is another hallucinogen of the tryptamine family. How does the drug work? Despite its creation decades ago, not much is known about how DiPT works. Zeus Tipado, a psychedelic neuroscience researcher, states that researchers know that the drug affects the same region…

WednesdayNov 02, 2022 1:33 pm

Research Finds That Psychedelics Users Are More Connected to Nature

We are currently in the midst of a major psychedelics renaissance. Decades after the United States outlawed the production, purchase and consumption of psychedelic drugs such as LSD and MDMA, states are loosening their psychedelic policies and allowing for more research into these mind-altering drugs. Furthermore, a growing number of people are using psychedelics for recreational and medical purposes, with a recent study finding that around 28% of Americans have used LSD, MDMA, ketamine, DMT, mescaline, salvia or psilocybin. A new study has now found that individuals who consume hallucinogenic drugs such as psilocybin tend to be more connected to…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Month: November 2022